ACE2 and COVID-19: By presenting evidence, we support the notion that SWTI has the potential to inhibit SARS-CoV-2 infection by targeting the ACE2 and TMPRSS2 pathways, suggesting that it could be a promising nutraceutical for the development of COVID-19 therapies.